CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

S Loi; S Pommey; B Haibe-Kains; PA Beavis; PK Darcy; MJ Smyth; J Stagg

Journal article

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

S Loi, S Pommey, B Haibe-Kains, PA Beavis, PK Darcy, MJ Smyth, J Stagg

Proceedings of the National Academy of Sciences of the United States of America | Published : 2013

DOI: 10.1073/pnas.1222251110

Abstract

Using gene-expression data from over 6,000 breast cancer patients, wereport herein that high CD73 expression is associated with a poor prognosis in triple-negative breast cancers (TNBC). Because anthracycline-based chemotherapy regimens are standard treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy. In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly associated with a lower rate of pathological complete response or the disappearance of invasive tumor at surgery. Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to ..

View full abstract

University of Melbourne Researchers

Sherene Loi Author

Paul Beavis Author

Phillip Darcy Author

Related Projects (3)

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

The role of CD73 in cancer

We here propose to investigate the role of a specific immune-suppressive molecule called CD73 in cancer. We will test the therapeutic activi..

Grants

Funding Acknowledgements

The authors thank Kathleen Spring, Bruno G. Leclerc, Isabelle Cousineau, Martin Turcotte, David Allard, Guillaume Chouinard, Francis Rodier, Guillaume Cardin, Nicole McLaughlin, Qerime Mundrea, and Ben Venville for technical support. This work was supported in part by Susan G. Komen for the Cure (IIR12221504); the National Health and Medical Research Council of Australia (1013667, 1007902); the Victorian Cancer Agency (EOI09_71); the Canadian Institutes of Health Research; the Cancer Research Society of Canada; a National Health and Medical Research Council early career Fellowship and Fonds J. C. Heuson (to S.L.); a National Health and Medical Research Council Career Development Award 2 award (to P.K.D.); National Health and Medical Research Council Australia Fellowship 628623 (to M.J.S.); and the Famille Jean-Guy Sabourin Research Chair of University of Montreal (J.S.).